Abzena

Mr Jonathan Robinson
Senior Director Scientific Affairs 
Mr David Lustig
Vice President, Business Development 

CLINICAL ACCELERATOR

Dr NIKOLAI NIKITIN
DIRECTOR 

Cypralis

Website:
www.cypralis.com
keywords
biopharmaceutical
Mr Simon Kerr
Chief Executive Officer 
Dr Michael Peel
Chief Scientific Officer 

Enesi Pharma Limited

Mr David Hipkiss
Chief Executive Officer 
Dr Ludovic Bonnet
VP Product Development 

Image Analysis Group

IA-Group is a strategic partner to bio-pharmacutical companies. We bring extensive therapeutic knowledge and regulatory expertise in strategic use of clinical imaging to enhance understanding of the mode of action, to increase the efficiency of clinical decisions and to accelerate drug development. IA‘s operations team leverage our global footprint and the next-generation cloud based proprietry platform Dynamika to de-risk trial execution and to ensure data quality and integrity. Our venture arm pioneer unique targeted investment and risk-sharing models to enable our clients to reach the next value inflection point faster. We fuse decades of theraputic insight and agile culture to meet today's speed and high standard of therapeutic innovation.

Organisation type
Dr Diana Roettger
Head of Scientific and Medical Affairs 

Inivata

Prof Clive Morris
Chief Executive Officer 
Dr Thomas Schlumpberger
VP Business Development 

Invisio Limited

keywords
pharmaceutical
Dr Bill Garner
Medical Director 
Mr Al Hansen
Chief Operating Officer 

MGB Biopharma Ltd

MGB Biopharma is a private company based in Glasgow, Scotland and is backed by a syndicate of Scotland’s leading angel investor groups together with Scottish Enterprise. Antimicrobial drug resistance is recognised as a global public health concern with an urgent need for new antibacterial drug classes that are more effective than existing treatments. MGB is developing the first truly novel class of anti-infectives in over a decade that has the potential to treat infections of a number of the most important susceptible and resistant pathogens.

keywords
biopharmaceutical
Organisation type
Dr Miroslav Ravic
CEO 
Mr Raymond Spencer
CFO 

OxStem Limited

OxStem is a drug discovery company, spun-out from the University of Oxford, with the unique vision of developing in-situ cell programming therapies to treat what are typically (but certainly not exclusively) age-related conditions, such as Dementia, Heart Failure, Macular Degeneration (the leading cause of blindness in the developed world), Diabetes and Oncology.

Website:
www.oxstem.com
Dr Carolyn Porter
Chief Business Officer 
Dr Michael Stein
CEO and Chairman 

Pneumagen Ltd

Website:
pneumagen.com
keywords
biopharmaceutical
Organisation type
Mr Douglas Thomson
Director